In 1995, Bausch + Lomb collaborated for a clinical trial with government researchers at the National Eye Institute. The goal: To see if a high dose nutrient formula can help people with Age-related Macular Degeneration (AMD).
NEI researchers concluded their first five-year clinical Age Related Eye Disease Study (AREDS).
4,757
Study participants ages 55 to 80 years, with and without AMD.
19%
Reduced risk of moderate vision loss after five years.
25%
Reduction in risk of AMD progression in those with moderate to advanced AMD.
10 Years
Participants showed continued effects at study follow-up in 2006.
Based on new learnings around AMD, the NEI researchers sought to improve the original AREDS formula.
The result was an updated formula that replaced beta-carotene with lutein and zeaxanthin, since new research suggested an association between beta-carotene and an increase in the risk of lung cancer among those with a history of smoking.2
4,203
Study participants ages 50 to 85, with AMD.
82
Clinical centers across the U.S.
5 Years
Length of AREDS2 study.
18%
Reduced risk of progressing to advanced AMD, compared to patients taking the original AREDS formulation.1
1. No clinically statistically significant differences in AEs between treatment groups. Post-hoc subgroup analysis 2. Johnson EJ. Curr Opin Clin Nutr Metab Care. 2010;13(1):28-33
The NEI recommends taking a vitamin formula that contains the exact nutrients based on the AREDS2 study for helping to reduce the risk of progression in moderate to advanced AMD.
* Percent Daily Values (DV) Based on a 2000-calorie diet **Daily value not established
The National Eye Institute is working on its report of the AREDS2 10-year study results.
No clinically or statistically significant AEs between treatment groups,1 but eliminating beta-carotene was associated with reduced risk of lung cancer in patients with a history of smoking (P=.04).2
No side effects were observed in patients who received a formula with 80 mg zinc per day.
No significant correlation was established for EPA + DHA supplementation with the progression of AMD.
You are now leaving the PreserVision® website and are going to a website that Bausch Health does not operate and to which Bausch Health’s Privacy Policy does not apply. Bausch Health is not responsible for the content, format, maintenance, or policies of the website you are about to visit and does not endorse or monitor any content on such website.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
†Compared to original PreserVision AREDS 2 Soft Gels
Text Size:A−A+